CAR T Therapy Clears Liver Cancer in Child
Researchers report complete regression of hepatoblastoma in a 3-year-old after an experimental GPC3-targeted CAR T cell treatment.
Updated on Nov. 21, 2026 in Cancer

A 3-year-old boy with hepatoblastoma that had spread to his lungs and bones showed complete regression after two infusions of an experimental CAR T cell therapy. The treatment was tested in the CARE study, the first human trial of this experimental form of CAR T therapy.
Why it matters
The cancer had returned rapidly despite chemotherapy and surgery, leaving few options for children with advanced liver tumors. Researchers say they will need to see how other patients respond before judging how effective and safe the GPC3-CAR treatment is.
This single-patient case report from the first-in-human CARE study measured an 11.2 cm by 9.6 cm by 7.1 cm liver tumor that resolved after three chemotherapy cycles and two GPC3-CAR infusions given eight weeks apart. Whether the response will hold across other patients has not yet been established.
The players
Baylor College of Medicine
A private medical school in Houston, Texas, where the CARE study of the GPC3-CAR treatment is being conducted.
Seattle Children's Hospital
A pediatric hospital in Seattle that is the site of the IMPACT trial testing the GPC3-CAR treatment.
The details
Hepatoblastoma is a liver cancer that affects young children. The GPC3-CAR therapy was engineered to recognize glypican-3, a protein highly expressed in liver cancers, and to express interleukin-15 and interleukin-21 to boost the CAR T cells' longevity and tumor-killing ability. The boy was enrolled after the cancer rapidly returned with a new lung tumor.
Timeline
The boy remained disease-free for 12 months after treatment.
Research Context
The result comes from the CARE study at Baylor College of Medicine, the first human trial of an experimental CAR T therapy engineered to target GPC3. The IMPACT trial at Seattle Children's Hospital is continuing to test the same treatment.
For families of children with advanced liver tumors, this experimental approach is still in early testing and is not yet a standard option. Access currently depends on enrollment in ongoing trials such as CARE and IMPACT.
The takeaway
Single-patient results are an early signal, not proof of benefit. Families weighing experimental options should discuss trial eligibility and risks with their pediatric oncology team.
Further reading
Explore more on Cancer research and treatment advances.
Source note: This article includes information reported by ScienceAlert.






